Companies › Binhui Biopharmaceutical
3 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OH2 Injection Oncolytic type 2 herpes simplex virus | – | Phase 3 | Melanoma; Advanced Liver Cancer; Solid Tumor | Mar 2027 |
| OH2 Oncolytic Type 2 Herpes Simplex Virus expressing GM-CSF | – | Phase 1 | Solid Tumor | Dec 2027 |
| Pucotenlimab (HX008) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Solid Tumor; Melanoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05698459 | OH2 Injection | Phase 1 | Advanced Liver Cancer | Oncology | Aug 2025 |
| NCT03866525 | OH2 | Phase 1 | Solid Tumor | Oncology | Aug 2025 |
| NCT03866525 | Pucotenlimab (HX008) | Phase 1 | Solid Tumor | Oncology | Aug 2025 |
| NCT04616443 | OH2 Injection | Phase 1 | Melanoma | Oncology | Nov 2025 |
| NCT04616443 | Pucotenlimab (HX008) | Phase 1 | Melanoma | Oncology | Nov 2025 |
| NCT05868707 | OH2 Injection | Phase 3 | Melanoma | Oncology | Mar 2027 |
| NCT07382531 | OH2 Injection | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT07382531 | OH2 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
Shanghai Juncell Therapeutics Guangzhou Gloria Biosciences CrystalGenomics Immorna Biotherapeutics Orca Biosystems
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.